

SIX SIMPLE STEPS TO SUBMITTING A REFERRAL
1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name _____ Address _____ City, State, ZIP _____

Preferred Contact Methods _____ Phone (to primary # provided below) _____ Text (to cell # provided below) _____ Email (to email provided below) _____

Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone _____ Alternate Phone _____ Date of Birth _____ Gender _____ Male _____ Female _____

Email _____ Last Four of SSN _____ Primary Language _____

2 PRESCRIBER INFORMATION

Prescriber's Name _____ State License Number _____

NPI Number _____ DEA Number _____ Group or Hospital _____

Address _____ City, State, ZIP _____

Phone _____ Fax _____ Contact Person _____ Contact's Phone _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date _____ Ship to _____ Patient _____ Office _____ Other _____

Diagnosis (ICD-10):
 E22.0 acromegaly and pituitary giantism _____ Other Code _____ Description _____

Patient Clinical Information

Allergies _____ Height _____ in/cm Weight _____ lb/kg

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Cinqair (reslizumab)	100 mg / 10 mL vial	Inject 3 mg/kg once every 4 weeks by IV infusion over 20 to 50 minutes Include sodium chloride and supplies sufficient for medication days supply • IV administration/infusion set (0.2micron filter) • IV Cath Insyte autoguard or PIV insertion kit • Ultrasyte needle-free connector (one per vial shipped) • 30mL syringe (one per vial shipped) • 50mL 0.9% NaCl • 2 – 10mL 0.9% NaCl flush • Alcohol swabs	Quantity: vials 30-day supply 90-day supply -day supply Refills: 1 year Other:
Dupixent (dupilumab)	200 mg/1.14ml PFS 300 mg/2mL PFS	Initial Dose: Inject 400mg SC (2-200mg injections in different injection sites) initially then 200mg SC every other week Inject 600mg SC (2-300mg injections in different injection sites) initially then 200mg SC every other week Maintenance Dose: Inject 200mg (one injection) SC every other week Inject 300mg (one injection) SC every other week	Quantity: Refills:

5 PHYSICIAN SIGNATURE REQUIRED

Product Substitution Permitted _____ (Date) _____ Dispense as Written _____ (Date) _____

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.

Please complete Patient and Prescriber information

Patient Name:

Patient Date Of Birth:

Prescriber Name:

Prescriber Phone:

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Fasenra (benralizumab)	30 mg/mL pre-filled syringe	Administer 30mg/mL by subcutaneous injection every 4 weeks for the first 3 doses, followed by injection once every 8 weeks thereafter Other: Administer	Quantity: 1 pre-filled syringe 3 pre-filled syringes Refills: 1 year Other:
Nucala (mepolizumab)	100 mg vial	SEVERE ASTHMA Inject 100 mg subcutaneously once every 4 weeks into the upper arm, thigh or abdomen EOSINOPHILIC GRANULOMATOSIS WITH POLYAGNIITIS (EGPA) Inject 300 mg as 3 separate 100mg subcutaneous injections once every 4 weeks into the upper arm, thigh or abdomen Include sterile water and supplies sufficient for medication days supply No supplies requested (supplies will be sent with shipment unless indicated) • One 10 mL vial sterile water for injection for every vial of Nucala® dispensed • Alcohol swabs • 3 mL Luer Lock injection syringe • NDL 21G needle for reconstitution • 1 mL polypropylene syringe with 21G to 27G x ½" needle for subcutaneous injection	Quantity: 30-day supply 90-day supply -day supply Refills: 1 year Other:
Xolair (omalizumab)	Vial 150 mg vial kit PFS 75mg/0.5ml pre-filled syringe 150mg/1ml pre-filled syringe	Every 4 weeks dosing: Administer 75 mg per dose subcutaneously every 4 weeks Administer 150 mg per dose subcutaneously every 4 weeks Administer 225 mg per dose subcutaneously every 4 weeks Administer 300 mg per dose subcutaneously every 4 weeks Other: Administer mg per dose subcutaneously every 4 weeks Every 2 weeks dosing: Administer 225 mg per dose subcutaneously every 2 weeks Administer 300 mg per dose subcutaneously every 2 weeks Administer 375 mg per dose subcutaneously every 2 weeks Other: Administer mg per dose subcutaneously every 2 weeks For Xolair Vials only: Include sterile water and supplies sufficient for medication days supply No supplies requested (supplies will be sent with shipment unless indicated) • One 10 mL vial sterile water for injection for every vial of Xolair® dispensed • Alcohol swabs • Flexible bandages 1" x 3" • 3 mL Luer Lock injection syringe • NDL 18G x 1½" Safety Glide needle for reconstitution • NDL 25G x ⅝" Safety Glide needle for subcutaneous injection	Quantity: 30-day supply 90-day supply -day supply Refills: 1 year Other:

5 PHYSICIAN SIGNATURE REQUIRED

Product Substitution Permitted

(Date)

Dispense as Written

(Date)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.

Please complete Patient and Prescriber information

Patient Name:

Patient Date Of Birth:

Prescriber Name:

Prescriber Phone:

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Other:	Other:	Other:	Quantity: Refills:
Epipen	Other:	Use as directed.	Quantity: 1 Refills:
Epipen Jr.	Other:	Use as directed.	Quantity: 1 Refills:

5 PHYSICIAN SIGNATURE REQUIRED

Product Substitution Permitted

(Date)

Dispense as Written

(Date)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.